Journal: medRxiv

Article Title: Variant-specific humoral immune response to SARS-CoV-2 escape mutants arising in clinically severe, prolonged infection

doi: 10.1101/2024.01.06.24300890

Figure Lengend Snippet: (a) Duration of hospitalisation (grey bar), time point of first vaccination (asterisc) and detection of SARS-CoV-2 RNA in nasopharyngeal swabs by qRT-PCR. Positive and negative PCR results are indicated by squares and crossed-out squares, respectively. The day of sampling after the initial diagnosis (day 1) is indicated. (b) Time course of the administration and dosage of antiviral therapeutics; the timeline of sampling is indicated in panel d. (c) Relative viral load in nasopharyngeal swabs during the first episode as measured by Ct values of qRT-PCR, for the timeline of sampling see panel d. (d) Mutations detected in S during the first episode. The repeated detection of mutations in consecutive samples is marked with a grey line. GISAID accession numbers of viral genome sequences are given in . The day of sampling after the initial diagnosis (day 1) is indicated.

Article Snippet: We applied the CE/IVD certified cPass TM SARS-CoV-2 Neutralization Antibody Detection Kit (GenScript Biotech, Mainz, Germany) to assess the neutralisation capacity of patient antibodies.

Techniques: Quantitative RT-PCR, Sampling